波士顿科学

Boston Scientific's 15min chart signals bearish trends with MACD, BB, and KDJ crosses.

Boston Scientific

Boston Scientific's 2026 Guidance Praised as 'Reasonable' by RBC Analysts

Sysco

Top Oversold Large-Cap Stocks: Sysco and Boston Scientific Lead the Way

Boston Scientific Stock Price Outlook: Is a 40% Surge Possible?

Boston Scientific's 15min chart shows MACD Death Cross, Bollinger Bands Narrowing.

Catalyst<ul> <li>Most analysts rate BSX Buy or Strong Buy showing broad institutional optimism.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a weak state and we need to pay attention to the risk of decline.</li> <li>Fund flows are trending negative across all order sizes indicating outflows from the stock.</li> <li>Bearish signals are obviously dominant with 3 bearish versus 0 bullish technical signals.</li></ul>

Key Factors

Boston Scientific (BSX) reported a 9.02% decline in stock price on April 1, 2026, closing at a two-year low amid high trading volume and ongoing investor concerns over legal and operational developments. Positive trial results for Boston Scientific's WATCHMAN FLX device in the CHAMPION-AF study showed non-inferior stroke prevention compared to NOACs and reduced bleeding risk, positioning it as a potential first-line treatment option. Raymond James downgraded Boston Scientific to Outperform from Strong Buy, lowering its price target to $88 from $97 due to slower growth in U.S. electrophysiology and the Watchman device segment. Boston Scientific's 15-minute chart exhibited a MACD Death Cross and Bollinger Bands narrowing on April 1, 2026, indicating bearish momentum and potential for continued downward movement in the stock price. RBC Capital raised Boston Scientific's price target to $115 and reiterated an Outperform rating, citing strong trial results for stroke risk reduction devices that could drive future growth.

Recent Updates

BSX News